Aemetis (AMTX) Stock Forecast & Price Target

Aemetis is viewed favorably because Q2 2026 showed meaningful operational improvement, with revenue of $63 million versus $52 million a year earlier and better-than-expected EPS of $(0.16), alongside strong gains in gross margins, operating income, and EBITDA. Its growth case is reinforced by tangible project execution, including biogas expansion to 15 dairies, 40 miles of pipeline installed, over 50 dairy agreements signed, and 6 more near completion, while the India business rebounded to $11 million in Q1 2026 and is on track for an IPO in 2026. The outlook is further supported by regulatory and strategic catalysts such as expanded E15 usage, CARB RNG pathway approval, Section 45Z credits extended to 2029, and progress on Sustainable Aviation Fuel, renewable diesel, and carbon sequestration projects, all of which could improve profitability from an already attractive low base.

Aemetis is weighed down by persistent net losses, including an $11 million loss versus an expected $24 million loss and a prior $22 million loss versus an expected $15 million loss, showing limited earnings traction despite operating in renewable fuels and biochemicals. Its financial plan has repeatedly been pushed out—from reaching $1 billion in revenue in 2025 to 2026, and $2 billion from 2027 to 2028—suggesting execution risk and slower-than-anticipated commercialization. The balance sheet is also highly leveraged, with about $1 million to $5 million in cash against $533 million to $546 million in debt, leaving it exposed to liquidity, regulatory, and commodity-price pressures.